Creative Medical Technology Holdings Inc (CELZ)

[uvaphd]

That’s total BS: the bottom was falling out with CaverStem LONG before COVID developed into a full-scale problem in the US near the END of Q1 2020. Go back and look at the absurdly low revenues generated by the company for all of 2018 and especially 2019, when “commercialization” was supposedly taking place. Moreover, with principals, including Dr. G. touting the efficacy of CaverStem repeatedly on social media in early and mid 2018, a huge amount of attention (and money) came here, the result of which drove the PPS from around .018 (where I got in roughly) up to .07–only to crash down all the way to .0002 and a 1:150 R/S. In what weird universe is this “protecting shareholder value”? Trust me, I know plenty about CELZ—much that many here (who are mostly newbies) probably haven’t even heard of. Since these all failed to materialize in an adequately visible way that would support and increase the PPS (the only really meaningful measure of a public company’s success), the leaders should be held to account for these failures: Russia contract, cachexia indications, woefully anemic growth of CaverStem despite the hiring of Gary Mells and whoever that female marketer was that had previously worked for Dr. G.’s clinic (I can’t recall her name). I could go on, but that’s a good start...